NASDAQ: PYXSPyxis Oncology Inc Stock
$2.21+0.28 (+14.51%)
Updated Mar 24, 2023
PYXS Price
$2.21
Fair Value Price
N/A
Market Cap
$81.73M
52 Week Low
$1.10
52 Week High
$5.00
P/E
-0.61x
P/B
0.51x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$120.72M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.31
Operating Cash Flow
-$89M
Beta
0.68
Next Earnings
Mar 28, 2023
Ex-Dividend
N/A
Next Dividend
N/A
PYXS Overview
Pyxis Oncology, Inc. is a preclinical stage biopharmaceutical company developing cancers therapies. Its product candidate, PYX-106, targets thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. PYX-102 is an investigational immune-therapeutic for treatment of solid tumors. Pyxis Oncology was incorporated in 2018 and is headquartered in Cambridge, MA.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PYXS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PYXS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PYXS is good value based on its book value relative to its share price (0.51x), compared to the US Biotechnology industry average (4.89x)
P/B vs Industry Valuation
PYXS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more PYXS due diligence checks available for Premium users.
Be the first to know about important PYXS news, forecast changes, insider trades & much more!
PYXS News
Valuation
PYXS fair value
Fair Value of PYXS stock based on Discounted Cash Flow (DCF)
Price
$2.21
Fair Value
$7.54
Undervalued by
70.68%
PYXS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PYXS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.61x
Industry
17.88x
Market
21.37x
PYXS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.51x
Industry
4.89x
PYXS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PYXS's financial health
Profit margin
Revenue
$0.0
Net Income
-$36.1M
Profit Margin
0%
PYXS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$211.4M
Liabilities
$50.6M
Debt to equity
0.31
PYXS's short-term assets ($186.61M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PYXS's short-term assets ($186.61M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PYXS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$17.4M
Investing
-$1.9M
Financing
$0.0
PYXS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PYXS vs Biotech Stocks
Pyxis Oncology Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.